The introduction of propofol in the 1980s led to resurgence in the development of total intravenous anesthesia (TIVA) since the loss of clinical interest due to the morbidity associated with the use of althesin and etomidate. Propofol has fewer side effects and a better pharmacokinetic profile for use in TIVA [1, 2]. Earlier recovery, compared with traditional anesthetic techniques, following its use has also been demonstrated, particularly in surgery of short to intermediate duration [3, 4].